Treatments

*March 2024* The phase 3 MARIPOSA trial (NCT04487080) evaluating a regimen of amivantamab-vmjw (Rybrevant) and lazertinib vs standard-of-care osimertinib (Tagrisso) for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. The combination demonstrated a longer progression-free survival (PFS) and duration…

*March 2024* Note to reader: Although Tagrisso is the preferred first-line treatment, some patients who took a 1st or 2nd generation drug as first-line (Tarceva, Afatinab) and then Tagrisso as second-line experienced a much longer PFS (progression-free survival) than those who started with Tagrisso. ABSTRACT Here, I suggest that while…

*March 2024* Abstract Introduction Characteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. Methods Clinical characteristics and outcomes were abstracted from the electronic…

*January 2024* Abstract Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-related lung cancers continue to account for the majority of diagnoses, smoking rates have been decreasing for several decades. Lung cancer in individuals who have never smoked (LCINS) is estimated to be the fifth most…

*March 2024* The publishing of data from the FLAURA21 and MARIPOSA2 trials in the fall of 2023 spurred much discussion and debate about the use of first-line chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR mutations. To clarify the role of first-line chemotherapy in this population, Suresh S. Ramalingam, MD,…

*March 2024* Stephen V. Liu, MD, Director of Thoracic Oncology and Head of Developmental Therapeutics, Georgetown University, gave an overview of the topics discussed during February’s IASLC Targeted Therapies Meeting. Isabel Preeshagul, DO, MBS, moderated the discussion. Watch it here.

*February 2024* Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers at Weill Cornell Medicine have developed a mouse model that illuminates this problematic process, known as…

*February 2024* Abstract Patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small-cell lung cancer represent a distinct subgroup of individuals who can experience initially tolerable and durable effects with first-line EGFR-directed tyrosine kinase inhibitors. Unfortunately, acquired treatment resistance and cancer progression within the CNS are inevitable during the disease course and present…

*April 2024* Highlights Additional frontline options for treating EGFR-mutated NSCLC are required. Lazertinib showed promising efficacy and safety in LASER201 and LASER301 trial. Long-term follow-up in LASER201 showed long PFS and OS with frontline lazertinib. Patients with and without baseline brain metastasis showed clinical benefit. Lazertinib was well tolerated, consistent…